25892-08-4

Basic information

• Product Name: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE
• Synonyms: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE;N-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE;N-(2,6-Difluoro-3-nitrophenyl)acetaMid;N-(2,6-Difluoro-3-nitrophenyl)
• CAS NO: 25892-08-4
• Molecular Formula: C₈H₆F₂N₂O₃
• Molecular Weight: 216.14
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 25892-08-4.mol

Chemical Properties

• Melting Point: 148 °C
• Boiling Point: 352.7 °C at 760 mmHg
• Flash Point: 167.1 °C
• Appearance: /
• Density: 1.513 g/cm³
• Vapor Pressure: 3.77E-05mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.03±0.70(Predicted)
• CAS DataBase Reference: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE(25892-08-4)
• EPA Substance Registry System: N1-(2,6-DIFLUORO-3-NITROPHENYL)ACETAMIDE(25892-08-4)

Safety Data

• Hazardous Substances Data: 25892-08-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N1-(2,6-Difluoro-3-nitrophenyl)acetamide is used as a building block in organic synthesis for the creation of pharmaceuticals and other biologically active compounds. Its unique structure, which includes a nitro group and fluorine atoms, contributes to the diversity of molecules that can be synthesized, offering a wide range of applications in drug development.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, N1-(2,6-Difluoro-3-nitrophenyl)acetamide is utilized as a key intermediate in the synthesis of new pharmaceutical agents. Its presence in the molecular structure can influence the pharmacological properties of the final product, making it a valuable component in the design and synthesis of novel therapeutics.
Used in Agrochemical Development:
N1-(2,6-Difluoro-3-nitrophenyl)acetamide may also find applications in the development of agrochemicals. Its chemical properties could be harnessed to create new pesticides or herbicides, contributing to advancements in agricultural productivity and crop protection.
Used in Materials Science:
N1-(2,6-Difluoro-3-nitrophenyl)acetamide's potential applications extend to materials science, where it could be incorporated into the development of new materials with specific properties. Its unique molecular structure may contribute to the creation of materials with improved characteristics for various industrial applications.

InChI:InChI=1/C8H6F2N2O3/c1-4(13)11-8-5(9)2-3-6(7(8)10)12(14)15/h2-3H,1H3,(H,11,13)

Upstream product

• 5509-65-9 2,6-difluoroaniline 
• 3896-29-5 N-(2,6-difluorophenyl)acetamide 

Downstream Products

• 1437316-68-1 N-(3-((3-(9H-purin-6-yl)pyridin-2-yl)amino)-2,4-difluorophenyl)-4-fluorobenzenesulfonamide 
• 1380228-02-3 N-(3-((3-(9H-purin-6-yl)pyridin-2-yl)amino)-2,4-difluorophenyl)thiophene-2-sulfonamide 
• 1380228-04-5 N-(3-(3-(9H-purine-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl) propane-1-sulfonamide 
• 1269421-10-4 N-(3-amino-2,4-difluorophenyl)-2-methylpropane-1-sulfonamide 
• 1380227-96-2 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)propane-2-sulfonamide 
• 1392429-91-2 N-(3-amino-2,4-difluorophenyl)cyclopropanesulfonamide 
• 1380228-32-9 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)cyclopropanesulfonamide 
• 1380228-16-9 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)cyclohexanesulfonamide 
• 1380228-53-4 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide 

Relevant articles and documents

Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling

One of the challenges for targeting B-RafV600E with small molecule inhibitors had been achieving adequate selectivity over the wild-type protein B-RafWT, as inhibition of the latter has been associated with hyperplasia in normal tissues. Recent studies suggest that B-Raf inhibitors inducing the 'DFG-in/αC-helix-out' conformation (Type IIB) likely will exhibit improved selectivity for B-RafV600E. To explore this hypothesis, we transformed Type IIA inhibitor (1) into a series of Type IIB inhibitors (sulfonamides and sulfamides 4-6) and examined the SAR. Three selectivity indices were introduced to facilitate the analyses: the B-RafV600E/B-RafWT biochemical (bS), cellular (cS) selectivity, and the phospho-ERK activation (pA). Our data indicates that α-branched sulfonamides and sulfamides show higher selectivities than the linear derivatives. We rationalized this finding based on analysis of structural information from the literature and provided evidence for a monomeric B-Raf-inhibitor complex previously hypothesized to be responsible for the desired B-RafV600E selectivity.

PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A,X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

NEW PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I), wherein the groups R2 to R4 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A, X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

The electrophilic substitution of some 2,4- and 2,6- dihaloacetanilides

The orientation of electrophilic substitution of some 2,4- and 2,6-dihaloacetanilides has been examined by NMR methods. Mixed acid nitration of 2,6-dichloro and 2-chloro-6-methylacetanilides gave predominantly the 3-nitro derivatives.